Business
Press Release Jun 14 2021
Lupin Limited has informed the Exchange regarding a press release dated Jun 14, 2021, titled "Lupin receives UK marketing authorization for Luforbec�� 100/6 μg pMDI,first branded generic alternative to Fostair�� 100/6 μg pMDI for treatmentof Asthma & COPD.".
About this update from Lupin Limited
[{"type":"text","content":" Lupin Limited has informed the Exchange regarding a press release dated Jun 14, 2021, titled \"Lupin receives UK marketing authorization for Luforbec�� 100/6 μg pMDI,first branded generic alternative to Fostair�� 100/6 μg pMDI for treatmentof Asthma & COPD.\". View Attachment","length":436,"tagName":"div"}]